JMP analyst maintains Simulations Plus stock rating amid forecast cuts

JMP Securities maintained its Market Perform rating on Simulations Plus (SLP) while significantly lowering FY25 and FY26 revenue and adjusted EBITDA forecasts due to near-term macroeconomic uncertainty impacting biopharma clients; revenue estimates were cut by 13.2% and 17.4% for FY25 and FY26 respectively. This adjustment follows Simulations Plus's recent announcement of reduced fiscal 2025 revenue guidance and a restructuring plan involving a 10% workforce reduction and leadership changes, though the firm maintains confidence in SLP's competitive positioning. Despite the lowered outlook, Stephens maintained an Overweight rating while reducing its price target to $28, citing potential positives like product mix shifts and FDA support for biosimulation.

Analysis

Simulations Plus (NASDAQ:SLP) is navigating significant challenges, as reflected by JMP Securities maintaining its Market Perform rating while substantially reducing financial forecasts due to near-term macroeconomic uncertainty impacting SLP's biopharma clients. JMP lowered its fiscal year 2025 revenue estimate for SLP by 13.2% to $78.3 million and its adjusted EBITDA forecast to $22.0 million, with comparable reductions for fiscal year 2026. This analyst adjustment follows SLP's own recent downward revision of its fiscal 2025 revenue guidance to between $76 million and $80 million, and its third-quarter revenue projection to between $19 million and $20 million. In response to these market conditions, which include client funding issues and drug pricing challenges, SLP has initiated a restructuring plan involving a workforce reduction of approximately 10% and key leadership changes, such as the appointment of a new Chief Revenue Officer. The company's stock has declined over 30% in the past week and trades at a P/E ratio of 91.8x. Despite this, InvestingPro analysis suggests the stock is trading below its Fair Value and indicates strong financial health, citing a current ratio of 4.37. JMP Securities also expressed continued confidence in SLP's competitive positioning and its comprehensive solution suite, noting the company recently traded at 15.6 times JMP’s calendar year 2025 adjusted EBITDA estimate, an 11% premium to competitor Certara. Concurrently, analyst firm Stephens, while reducing its price target for SLP to $28 from $42, maintained an Overweight rating, highlighting potential positive factors like a shift in product mix and FDA support for biosimulation. Other corporate developments include the launch of DILIsym 11, an updated toxicology software, and the appointment of Grant Thornton LLP as its new independent auditor.

Key Decisions for Investors

• Investors should exercise caution given the significantly lowered revenue and EBITDA forecasts for FY25 and FY26 from JMP Securities, alongside Simulations Plus's own reduced guidance, reflecting substantial near-term uncertainty and contributing to the stock's recent sharp decline.
• Closely monitor the execution and financial impact of SLP's restructuring plan, including the 10% workforce reduction and leadership changes, for evidence of improved operational efficiency and ability to navigate the challenging biopharma client environment.
• Evaluate the current valuation, noting the high P/E ratio of 91.8x against InvestingPro's assessment of potential undervaluation and strong financial health (current ratio 4.37), while considering potential upside from new product launches like DILIsym 11 and supportive regulatory trends for biosimulation highlighted by Stephens.
• Re-assess SLP's valuation premium relative to competitor Certara, which JMP noted at 11% based on calendar year 2025 adjusted EBITDA estimates, in light of the company's revised and considerably lower growth outlook.